Literature DB >> 10486832

Immune responses in a horse inoculated with the VP2 gene of African horsesickness virus.

M Romito1, D H Du Plessis, G J Viljoen.   

Abstract

The ability of a DNA vaccine to elicit an immune response in a horse was evaluated. The outer capsid protein VP2 of African horsesickness virus is known to elicit protective immunity in horses. Reverse transcribed DNA of the gene encoding VP2 was placed under the transcriptional control of the cytomegalovirus immediate-early enhancer/promoter and was injected on several occasions intramuscularly into a horse. Low antibody levels could be detected by ELISA. Antibodies directed against VP2 alone were shown by Western blot while low levels of neutralizing antibodies were detected by a 50% plaque reduction assay. In contrast to a relatively poor humoral response, a significant lymphoproliferative response in the presence of whole virus proteins, as well as a cytotoxic cellular reaction against virus-infected syngeneic target cells was shown.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10486832

Source DB:  PubMed          Journal:  Onderstepoort J Vet Res        ISSN: 0030-2465            Impact factor:   1.792


  7 in total

1.  Multiserotype protection elicited by a combinatorial prime-boost vaccination strategy against bluetongue virus.

Authors:  Eva Calvo-Pinilla; Nicolás Navasa; Juan Anguita; Javier Ortego
Journal:  PLoS One       Date:  2012-04-13       Impact factor: 3.240

2.  Immunogenicity of recombinant VP2 proteins of all nine serotypes of African horse sickness virus.

Authors:  Yuta Kanai; Piet A van Rijn; Mieke Maris-Veldhuis; Yuki Kaname; T N Athmaram; Polly Roy
Journal:  Vaccine       Date:  2014-07-18       Impact factor: 3.641

3.  The immunogenicity of recombinant vaccines based on modified Vaccinia Ankara (MVA) viruses expressing African horse sickness virus VP2 antigens depends on the levels of expressed VP2 protein delivered to the host.

Authors:  Eva Calvo-Pinilla; Simon Gubbins; Peter Mertens; Javier Ortego; Javier Castillo-Olivares
Journal:  Antiviral Res       Date:  2018-04-18       Impact factor: 5.970

Review 4.  African Horse Sickness: A Review of Current Understanding and Vaccine Development.

Authors:  Susan J Dennis; Ann E Meyers; Inga I Hitzeroth; Edward P Rybicki
Journal:  Viruses       Date:  2019-09-11       Impact factor: 5.048

5.  Protection of IFNAR (-/-) mice against bluetongue virus serotype 8, by heterologous (DNA/rMVA) and homologous (rMVA/rMVA) vaccination, expressing outer-capsid protein VP2.

Authors:  Tamara Kusay Jabbar; Eva Calvo-Pinilla; Francisco Mateos; Simon Gubbins; Abdelghani Bin-Tarif; Katarzyna Bachanek-Bankowska; Oya Alpar; Javier Ortego; Haru-Hisa Takamatsu; Peter Paul Clement Mertens; Javier Castillo-Olivares
Journal:  PLoS One       Date:  2013-04-12       Impact factor: 3.240

6.  Vaccination of horses with a recombinant modified vaccinia Ankara virus (MVA) expressing African horse sickness (AHS) virus major capsid protein VP2 provides complete clinical protection against challenge.

Authors:  Berta Alberca; Katarzyna Bachanek-Bankowska; Marta Cabana; Eva Calvo-Pinilla; Elisenda Viaplana; Lorraine Frost; Simon Gubbins; Alicia Urniza; Peter Mertens; Javier Castillo-Olivares
Journal:  Vaccine       Date:  2014-05-14       Impact factor: 3.641

7.  Antiserum from mice vaccinated with modified vaccinia Ankara virus expressing African horse sickness virus (AHSV) VP2 provides protection when it is administered 48h before, or 48h after challenge.

Authors:  Eva Calvo-Pinilla; Francisco de la Poza; Simon Gubbins; Peter Paul Clement Mertens; Javier Ortego; Javier Castillo-Olivares
Journal:  Antiviral Res       Date:  2015-01-30       Impact factor: 5.970

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.